Adjusting Strategies Over a 25-Year-Long Career

Tris Pharmaceutical’s founder and CEO Ketan Mehta spoke with Pharmaceutical Executive about the company’s history and how it’s adapted over the decades. While the company initially focused on oral technology, it eventually broadened its scope and is working in areas such as pain management and addiction.

Mehta also discussed the ways that he ensures his company maximizes a drug’s impact and he experiences with a variety of regulatory environments.

Pharmaceutical Executive: How has your strategy at Tris Pharma changed over the past 25 years?
Ketan Mehta: I started Tris about 25 years ago. We actually started the company more on the technology side with a platform technology.

It was an oral technology, and then we evolved from there. We still continue to focus on our technology where the opportunity arises, but we have become focused on neurology and neuroscience.

We have a commercial portfolio of ADHD products and a pipeline that includes treatments for narcolepsy, spasticity, pain, and addiction. We also have a technology-based pipeline we continue to focus on.